A Comprehensive Literature Review of JAK Inhibitors in the Treatment of Alopecia Areata

The comprehensive literature review on JAK inhibitors for treating alopecia areata (AA) highlighted the promising efficacy of these inhibitors, particularly tofacitinib and ruxolitinib, in promoting hair regrowth in patients with various forms of AA, including severe cases like alopecia universalis. Multiple studies and case reports demonstrated significant hair regrowth and improvement in nail dystrophy associated with AA. However, the review also noted variability in patient responses and the need for further research to optimize dosing and long-term safety. The findings underscored the potential of JAK inhibitors as a viable therapeutic option for AA, with ongoing studies aiming to refine their use and address any associated risks.